Skip to main content

Tissue Factor-Dependent Chemokine Production Aggravates Experimental Colitis


Tissue factor (TF) is traditionally known as the initiator of blood coagulation, but TF also plays an Important role In inflammatory processes. Considering the pivotal role of coagulation in inflammatory bowel disease, we assessed whether genetic ablation of TF limits experimental colitis. To this end, wild-type and TF-deficient (TFlow) mice were treated with 1.5% dextran sulfate sodium (DSS) for 7 d, and effects on disease severity, cytokine production and leukocyte recruitment were examined. Clinical and histological parameters showed that the severity of colitis was reduced in both heterozygous and homozygous TFlow mice compared with controls. Most notably, edema, granulocyte numbers at the site of inflammation and cytokine levels were reduced in TFlow mice. Although anticoagulant treatment with dalteparin of wild-type mice reduced local fibrin production and cytokine levels to a similar extent as in TFlow mice, it did not affect clinical and histological parameters of experimental colitis. Mechanistic studies revealed that TF expression did not influence the intrinsic capacity of granulocytes to migrate. Instead, TF enhanced granulocyte migration into the colon by inducing high levels of the granulocyte chemoattractant keratinocyte-derived chemokine (KC). Taken together, our data indicate that TF plays a detrimental role in experimental colitis by signal transduction-dependent KC production in colon epithelial cells, thereby provoking granulocyte influx with subsequent inflammation and organ damage.


Inflammatory bowel diseases are chronic and recurrent disorders of the gastrointestinal tract, of which both etiology and pathogenesis remain only partly understood (13). Crohn’s disease and ulcerative colitis, the two major forms of inflammatory bowel disease, are characterized by intestinal inflammation as a result of transmural infiltration of granulocytes, lymphocytes, monocytes or macrophages and plasma cells, accompanied by the excessive production of free oxygen radicals, ultimately leading to mucosal disruption and ulceration (4).

Inflammatory bowel disease patients have an approximately three-fold increased risk of venous thrombosis compared with age, sex and geographically matched controls (5), and these thrombotic complications significantly contribute to morbidity and mortality (6,7). The frequency of venous thrombosis in patients suffering from inflammatory bowel disease lies between 1 and 8%, whereas postmortem studies show thrombotic events in up to 40% of patients (8). Thrombotic risk increases with active disease, although >30% of patients have inactive disease at the time thrombosis is diagnosed (6). Overall, it is thus apparent that a “hypercoagulable state” is frequently observed during inflammatory bowel disease and that coagulation abnormalities are an intimate part of the clinical picture of inflammatory bowel disease (9). However, whether exacerbated coagulation participates in the etiology of inflammatory bowel disease remains controversial. It is interesting to note that the risk of inflammatory bowel disease is lower than expected in patients with inherited bleeding disorders (10) and that several observational studies show a beneficial effect of anticoagulant treatment (1114). However, a randomized clinical trial did not confirm this beneficial effect of heparin treatment (15). In line with a limited effect of blood coagulation in the etiology of inflammatory bowel disease, prothrombotic factor V Leiden mice were indistinguishable from wild-type animals in dextran sulfate sodium (DSS)-induced experimental colitis (16).

Tissue factor (TF), a 47-kDa transmembrane glycoprotein, initiates blood coagulation via formation of an enzymatic complex with factor (F)VIIa, eventually leading to the activation of thrombin and the formation of fibrin (17,18). Beyond its well-established role in coagulation, TF has been suggested to play a paramount role in inflammatory conditions. Indeed, TF may activate protease activated receptor (PAR) signaling leading to the production of (among others) inflammatory cytokines (19,20). The increase of both interleukin (IL)-6 and IL-8 levels in coagulating blood (21) is indicative of TF-induced cytokine production either through direct cellular effects or via downstream coagulation factors. Because lipopolysaccharide-induced IL-6 and keratinocyte-derived chemokine (KC) (a mouse analog of IL-8) production in cultured macrophages and in anticoagulated whole blood is lower in heterozygous TF-deficient cells than in wild-type cells, one might argue that TF influences cytokine production without intervention of other coagulation factors (22). The in vivo significance of TF for host defense is most evident because TF blocking agents reduce the risk of lipopolysaccharide-induced mortality. For instance, pre-treatment with a monoclonal TF antibody attenuates coagulopathy and mortality in a lethal Escherichia coli sepsis model in baboons (23). Moreover, immunization of mice with a polyclonal TF antibody protects against death upon administration of lethal amounts of lipopolysaccharide (24), whereas treatment with site-inactivated FVIIa delays or prevents death upon LD100 E. coli administration in baboons (25). In line with an important role of TF in inflammation, it was recently shown that a murine TF-blocking antibody reduced DSS-induced experimental colitis (26). Most prominently, blocking TF reduced blood cell recruitment and tissue injury in mice subjected to DSS-induced colitis. As expected, the TF-blocking antibody also reduced thrombin-anti-thrombin levels (TAT; a marker of ongoing coagulation), and it blunted thrombus formation in DSS-treated mice. This latter study thus shows that TF mediates inflammatory cell recruitment and tissue injury in the colon during experimental colitis. Although the authors suggest that the anticoagulant properties of TF may be important, the underlying mechanism by which TF aggravates experimental colitis remains elusive.

The current report aims to create better understanding of the role of TF in colitis and directly compares experimental colitis in mice with a genetic ablation of TF with wild-type mice treated with the anticoagulant dalteparin. Our data confirm the importance of TF in experimental colitis and extend these findings by providing evidence that TF aggravates colitis in a coagulation-independent manner. We suggest that TF-dependent signal transduction induces KC production in colon epithelial cells, thereby provoking granulocyte influx with subsequent inflammation and organ damage.

Material and Methods


TFlow mice, previously generated (27) and provided by Dr. Mackman (University of North Carolina, Chapel Hill, NC, USA), were bred at the animal care facility of the Academic Medical Center. Homozygous TFlow mice are mice deficient for murine TF that are rescued from embryonic lethality by introducing a human TF minigene containing the human TF promoter and human TF cDNA leading to TF activity of around 1% (relative to mouse TF). Heterozygous TFlow mice express 50% murine TF and also contain the human TF minigene. C57BL/6J wild-type mice were purchased from Charles River (Someren, the Netherlands). All mice were bred and maintained at the animal care facility at the Academic Medical Center according to institutional guidelines, with free access to food and water. Animal procedures were carried out in compliance with the Institutional Standards for Humane Care and Use of Laboratory Animals. All mice were housed in the same temperature-controlled room with alternating 12-h light/dark cycles. Mice at an age of 8–10 wks were used in the colitis model as described below.

Induction of Colitis and Assessment of Disease Progression

Mice received 1.5% DSS (molecular weight of 40 kDa; TdB Consultancy, Uppsala, Sweden) in filter-purified drinking water for 7 d ad libitum as described before (16). Control mice received filtered water alone. For the anticoagulant experiments, mice received 80 IU/kg/d dalteparin (based on [28]). Body weight loss (calculated as the percentage difference between the original weight and the weight at the time of sacrifice) and stool consistency were used for clinical assessment of disease severity.

Histological Analysis

Histological analysis was performed essentially as described before (29,30). In detail, the longitudinally divided colons were rolled up, fixed in 4% formalin and embedded in paraffin for routine histology. The following parameters were scored in a blinded fashion by a pathologist: (i) percentage of area involved, (ii) number of follicle aggregates, (iii) edema, (iv) fibrosis, (v) erosion/ulceration and (vi) crypt loss and infiltration of (vii) mono- and (viii) polymorphonuclear cells. Percentage of area involved and crypt loss were scored on a scale ranging from 0 to 3 as follows: 0, normal; 1, <10%; 2, 10–50%; and 3, >50%. Erosions were defined as 0 if the epithelium was intact, as 1 for the involvement of the lamina propria, as 2 for ulcerations involving the submucosa and as 3 when ulcerations were transmural. The severity of the other parameters was scored on a scale of 0–3 as follows: 0, absent; 1, weak; 2, moderate; and 3, severe. The score ranges from 0 to a maximum of 24 points.

Cytokines and Chemokines Measurement

IL-6, monocyte chemoattractant protein (MCP)-1 and tumor necrosis factor (TNF)-α were measured in colon homogenates using the BD Cytometric Bead Array Mouse Inflammation Kit (Becton Dickinson, Lincoln Park, NJ, USA) as described before (31). Detection limits were 10 pg/mL. KC was measured using an enzyme-linked immunosorbent assay (ELISA) (R&D Systems, Minneapolis, MN, USA) according to the manufacturer’s instructions with a detection limit of 31.25 pg/mL.

Colon Tissue Culture

Colons, collected from wild-type and TFlow mice, were washed in Hanks’ balanced salt solution (HBSS) medium containing penicillin and streptomycin, after which colon sections of approximately 2 mm were placed in RPMI 1640 medium containing 1% fetal calf serum, penicillin and streptomycin. Colon sections were stimulated with FVIIa (10 and 100 nmol/L) for 24 h, after which the supernatant was collected for analysis of KC levels.


Rest material of ulcerative colitis patients was used for immunohistochemistry according to the guidelines of the Medical Ethical Committee of the Academic Medical Center (AMC), University of Amsterdam, Amsterdam, the Netherlands.


Colon sections were harvested, fixed, paraffin embedded and stained with hematoxylin and eosin according to routine procedures. For immunohistochemistry, 4-µm sections were deparaffinized, endogenous peroxidase activity was quenched with 0.3% hydrogen peroxide for 15 min at room temperature and antigen retrieval was performed for 10 min at 100°C in 10 mmol/L sodium citrate buffer, pH 7.4 (PAR-2 and TF stainings), for 15 min at 37°C with 0.025% pepsin in 0.1 mol/L HCl (granulocyte staining) or for 30 min at 37°C with 0.1% trypsin. After subsequent washing at room temperature and rehydration in phosphate-buffered saline, sections were blocked with TENG-T (100 mmol/L Tris-HCl, pH 8.0, 50 mmol/L EDTA, 1.5 mmol/L NaCl, 2.5% gelatin, 0.5% Tween) for 10 min (lymphocyte antigen 6 complex, locus G [LY-6G]) or with 10% normal goat serum in phosphate-buffered saline for 30 min (PAR-2) or with normal rabbit serum for 10 min (fibrin) and subsequently incubated with antibodies against LY-6G (fluorescein isothiocyanate labeled) (1:1,000; Pharmingen, San Diego, CA, USA), TF (1:50; American Diagnostica product number 4509; Stamford, CT, USA), PAR-2 (1:80; SAM11; Santa Cruz, CA, USA) or fibrin(ogen) (1:1,000; biotinylated goat anti-mouse fibrinogen antibody; Accurate Chemical and Scientific, Westbury, NY, USA [32]) overnight at 4°C. For LY-6G staining, the slides were first incubated for 15 min with a rabbit-anti-FITC antibody (1:1,000), after which the slides were incubated with the appropriate horseradish peroxidase-conjugated secondary antibodies. For fibrin stainings, slides were incubated for 30 min with avidin-biotin-peroxidase complex (DAKO K0355). For all stainings, 3,3′-diaminobenzidine (DAB) staining was used to visualize peroxidase activity. Slides were photographed with a microscope equipped with a digital camera (Leica CTR500; Leica Microsystems, Wetzlar, Germany). For granulocyte stainings, we scored the number of positive cells in 10 different fields (200× magnification).

Granulocyte Migration

Granulocytes were isolated from EDTA-anticoagulated blood by polymorphprep density gradient centrifugation (Axis-Shield, Oslo, Norway). Granulocytes were collected, diluted and labeled with CellTracker Green as described before (33,34). Briefly, the fluorescent dye was incubated with the cells for 30 min at 37°C. Cells were washed once in medium to remove excessive soluble dye and then incubated for 1 h at 37°C in medium without dye. Subsequently, cells (1 × 105) were transferred to 3 μmol/L pore size HTS FluoroBlok Cell Culture inserts, which were inserted in fitting 24-well plates containing IL-8 as the chemoattractant in the presence or absence of FVIIa. Promptly, fluorescence values representing the number of cells on the bottom side of the insert were read at 37°C on a Series 4000 CytoFluor Multi-Well Plate Reader (PerSeptive Biosystems, Framingham, MA, USA). The raw fluorescence data were corrected for background fluorescence and fading of the fluorophore; the data were then plotted with GraphPad Prism 4.

Data Analysis

Statistical analyses were performed using one-way analysis of variance, followed by the Mann-Whitney U test. All values are reported as means ± SE. Statistical significance was set at P < 0.05.


TFlow Mice Are Protected against DSS-Induced Colitis

The development of DSS-induced colitis was determined in wild-type, heterozygous and homozygous TFlow mice. Importantly, wild-type mice developed colitis, as evident from weight loss, reduced length of the colon and increased weight of the colon (Figure 1). Although the TFlow mice did develop colitis as well, it was clearly not as severe as in the wild-type mice. In detail, TFlow mice showed a clear reduction in weight loss compared with wild-type mice. Moreover, the colon length of wild-type mice that received DSS decreased by 23%, whereas the colon length decreased by about 10% for both homozygous and heterozygous TFlow mice. Finally, the colon weight increased by around 57% in wild-type animals, while in the TFlow animals, the colon weight increased by approximately 18% in homozygous TFlow animals and 27% in heterozygotes.

Figure 1
figure 1

TF deficiency reduces the severity of clinical indices of DSS colitis in mice. (A) TFlow mice fed 1.5% (w/v) DSS in their drinking water for 7 d were protected against body weight loss compared with wild-type mice. The TFlow mice presented smaller changes in colon length (B) and colon weight (C) (shown in mg/cm) than wild-type mice. Data are means ± SEM (n = 7). *P < 0.05, **P < 0.01, ***P < 0.001.

Reduced Inflammation and Coagulation in TFlow Mice

To confirm the macroscopic data showing that TFlow mice are protected against DSS-induced colitis, we next scored edema, crypt loss, granulocytes, mononuclear cells, fibrosis and ulceration on HE-stained colon slides (Figure 2A). This disease severity score increased from 1 in control animals to 12.8 ± 1.1 in DSS-treated wild-type mice and 10.2 ± 2.1 or 7.8 ± 3.4 in DSS-treated heterozygous and homozygous TFlow mice, respectively (Figure 2B). Most importantly, the number of granulocytes and edema were significantly reduced in TFlow compared with wild-type mice. As shown in Figure 2C, Ly-6G stainings confirm the reduced number of granulocytes in the TFlow mice. In line with these reduced granulocyte numbers, DSS-induced inflammatory cytokine production was dramatically diminished in wild-type mice compared with both heterozygous and homozygous TFlow mice (Figure 2D). To assess local coagulant activity, we scored the levels of fibrin(ogen) in the colon of DSS-treated or untreated control animals. As shown in Figure 2E, DSS induces the level of fibrin(ogen) in both wild-type and TFlow animals. Interestingly, however, fibrin(ogen) levels were significantly reduced in a dose-dependent manner in the TFlow mice.

Figure 2
figure 2

TFlow mice present reduced inflammation and coagulation during experimental colitis. (A) Hematoxylin and eosin staining of colon sections of wild-type and TFlow mice show that inflammation is less prominent in TFlow than in wild-type mice. (B) The total histopathological score is reduced in TFlow mice in comparison to wild-type mice. (C) Granulocyte infiltration is specifically decreased in colon sections of TFlow mice compared with wild-type mice, as shown by LY-6G staining. (D) Decreased levels of inflammatory cytokines in colon homogenates of TFlow mice. (E) Reduced levels of fibrin(ogen) in TFlow mice compared with control animals. Data are means ± SEM (n = 7). *P < 0.05, **P < 0.01, *** P < 0.001.

Anticoagulant Treatment Does Not Limit DSS-Induced Colitis

TF may exert its aggravating effect in colitis by either its procoagulant activity or by its cellular signaling properties. To discriminate between these two potential mechanisms by which TF is detrimental, we evaluated the effect of anticoagulant treatment in DSS-induced colitis. As shown in Figure 3A, dalteparin treatment did significantly reduce DSS-induced colonic levels of fibrin(ogen) to similar levels as observed in DSS-treated heterozygous TFlow mice. Interestingly, however, dalteparin treatment did not protect mice against DSS-induced colitis as opposed to TFlow mice. As shown in Figure 3B, clinical parameters of experimental colitis tested (body weight loss, colon length and colon weight) were not significantly different in dalteparin-treated versus -untreated control mice.

As shown in Figure 3C, dalteparin treatment did limit DSS-induced proinflammatory cytokine production, although not as dramatically as in TFlow mice (compare Figures 2D and 3C). However, the reduced cytokine levels do not diminish tissue damage, as evident from similar scores for edema, crypt loss, granulocytes, mononuclear cells, fibrosis and ulceration (Figure 3D). Ly-6G stainings do not show any difference in the number of granulocytes in dalteparin-versus control-treated mice (Figure 3E), although KC levels were reduced in the dalteparin-treated mice.

Figure 3
figure 3

Anticoagulant treatment does not ameliorate DSS-induced colitis. (A) Dalteparin treatment does reduce the levels of fibrin(ogen) in DSS-treated animals. (B) Dalteparin does not limit DSS-induced changes in body weight and colon length or weight. (C) Cytokine levels in colon homogenates of dalteparin- and control-treated mice after 7 d DSS treatment. Histopathological score (D), number of LY-6G-positive cells and KC production (E) in dalteparin- and control-treated mice. Data are means ± SEM (n = 10). *P < 0.05. A.U., arbitrary units.

TF-Dependent Signaling in Colon Epithelial Cells Induces KC Levels

It is well accepted that granulocytes play a detrimental role during the development of inflammatory bowel disease. Interestingly, a major difference between wild-type animals and TFlow mice in response to DSS-induced colitis is the influx of granulocytes into the inflamed colon. This is particularly interesting because TF is known to influence cell migration (mainly in the setting of tumor cells) (35,36). Consequently, we determined whether TFlow granulocytes (obtained from TFlow mice) are affected in their migratory response compared with wild-type granulocytes. However, FVIIa-stimulated wild-type and TFlow granulocytes did migrate to IL-8 to a similar extent (data not shown). Thus, TF seems not to alter the intrinsic capacity of granulocytes to migrate into inflamed tissues.

An alternative explanation for the increased influx of granulocytes in wildtype versus TFlow colon might be the local expression of granulocyte chemoattractants (IL-8, or its murine homolog KC). Indeed, KC levels are high in colon homogenates of wild-type mice treated with DSS but not in both heterozygous and homozygous TFlow animals (Figure 4A). To support the hypothesis that low numbers of granulocytes in the colon of TFlow mice are due to impaired TF-dependent KC production, we first analyzed expression levels of TF and its cognate receptor PAR-2 in ulcerative colitis (Figure 4B) and Crohn’s disease patients (data not shown). As shown in Figure 4B, TF and PAR-2 expression is most prominent on colonic epithelial and goblet cells, although TF is also expressed on the inflammatory infiltrate. Next, we determined whether the colon would produce KC in response to FVIIa. Indeed, ex vivo stimulation of small colon sections obtained from wild-type animals with FVIIa significantly induced KC production in a dose-dependent manner (Figure 4C). Similar experiments using TFlow colon sections did not show increased KC production after FVIIa stimulation (Figure 4C). Finally, we stimulated colon sections with a PAR-2 agonist peptide and observed that PAR-2 activation also led to KC production, thereby suggesting an important role for TF/FVIIa/PAR-2 signaling in local KC production (data not shown).

Figure 4
figure 4

TF-dependent signaling in colon epithelial cells induces KC levels. (A) KC production in colon homogenates of wild-type and TFlow mice after 7 d DSS treatment. (B) TF and PAR-2 expression in colon sections of ulcerative colitis patients. (C) KC production after ex vivo stimulation of wild-type and TFlow colon section with FVIIa for 24 h. Data are means ± SEM of three independent experiments. *P < 0.05.


We studied the role of TF in DSS-induced colitis, and we have shown that TF deficiency protects mice from DSS-induced experimental colitis. Both homozygous as well as heterozygous, TFlow mice have significantly reduced scores for both clinical and histological parameters compared with wild-type mice. The reduced severity of experimental colitis correlated with reduced levels of proinflammatory cytokines in the TFlow mice, whereas the number of granulocytes at the site of inflammation was also significantly reduced in TFlow mice. These data are in perfect agreement with previous studies showing that a monoclonal TF-blocking antibody limits experimental colitis in wild-type animals (26), and our data thus underscore the importance of TF in inflammatory bowel disease.

To determine whether TF would aggravate experimental colitis by activating blood coagulation, wild-type mice were treated with the low-molecular weight heparin dalteparin. The selected dose of dalteparin is within the dose range used in patients and has previously been shown to effectively block coagulant activity and to limit murine diabetic nephropathy (28). However, dalteparin treatment did not ameliorate DSS-induced colitis, as evident from similar increases in colon weight, decreases in colon length and DSS-induced disease activity scores between treated and untreated animals. Although dalteparin treatment reduced fibrin levels and limited inflammatory cytokine production as efficient as heterozygous TF deficiency, anticoagulant treatment also did not limit granulocyte influx into the inflamed area. Thus, it seems that the procoagulant activity of TF does not significantly contribute to the development of experimental colitis. This result is particularly interesting considering the ongoing controversy on the importance of activated blood coagulation in inflammatory bowel disease. Indeed, a vascular component to the pathogenesis of inflammatory bowel disease was already proposed in 1934 (37), and small observational studies did show dramatic responses in patients with ulcerative colitis (1114). Nine out of ten patients on combined heparin and sulfasalazine therapy became asymptomatic, whereas patient number 10 had a partial response (12). Nadroparine treatment alone significantly improved endoscopic and histological signs of inflammation in 20 out of 25 patients (11), whereas dalteparin treatment resulted in complete remission in 6 out of 12 patients (13). Although a small clinical randomized trial could not confirm these beneficial effects (15), the inclusion criteria of mainly mildly affected patients and the short duration of LMWH treatment did not allow confirmative conclusions.

Probably the most important finding of our study is the large difference in influx of granulocytes into the inflamed colon between wild-type and TFlow mice in response to DSS treatment. This is particularly interesting, since granulocytes are of pivotal relevance in the clinical setting of inflammatory bowel disease, as evident from, for instance, the promising effect of Natalizumab and MLN02 for the treatment of Crohn’s disease and ulcerative colitis (38,39). Moreover, it is well know that TF induces migration of a large variety of cells (35,36). Although the presence of TF on granulocytes is under debate (40), we determined whether granulocytes derived from TFlow mice did have a hampered migratory capacity compared with granulocytes from wild-type mice. However, FVIIa-stimulated wild-type granulocytes migrated toward IL-8 as efficient as wildtype granulocytes, suggesting the observed differences in granulocyte influx are not due to the intrinsic migratory capacity of the granulocytes. Instead, we show that the low numbers of granulocytes in the colon of TFlow mice are most likely due to impaired TF-dependent KC production. Indeed, KC levels are significantly induced in wild-type mice treated with DSS but not in both homo- and heterozygous TFlow mice. In an apparent discrepancy, the absence of KC was previously shown to increase the susceptibility to DSS-induced colitis, mainly by preventing granulocyte infiltration into the inflamed colon (41). However, granulocyte numbers are tightly regulated during inflammatory conditions and both low as well as high numbers may be detrimental. Dalteparin treatment reduces KC levels in wild-type mice, but these levels are still significantly increased compared with TFlow animals. The decreased KC levels after anticoagulant treatment are most likely due to reduced thrombin levels. Indeed, it is well known that thrombin induces IL-8/KC levels in different cell types (42,43).

Interestingly, IL-8 (the human counterpart of KC) expression is significantly induced in the colonic mucosa of inflammatory bowel disease patients, and its expression is in direct proportion with the degree of inflammation (44,45), suggesting an essential role of IL-8 in the pathogenesis of inflammatory bowel disease. Moreover, colon epithelial cells are a known source of IL-8 in inflammatory conditions (46), and the FVIIa/TF complex was previously shown to induce IL-8 levels in several different cell lines (4749). In agreement, we show that ex vivo FVIIa-dependent KC production is dramatically reduced in TFlow colon sections compared with colon sections of wild-type mice. These data suggest an important role for the TF/FVIIa complex in KC production and subsequent granulocyte influx during colitis.

Our data suggest that the TF/FVIIa complex aggravates experimental colitis depending on the signaling properties of TF. In line with this notion, activation of PAR-2 by either the TF/FVIIa complex or agonist peptides leads to IL-8 production in several cell lines, including epithelial cells of the gastrointestinal tract (47,50,51), but also in the whole colon section (this report). Moreover, promoter methylation of PAR-2 seems to correlate with the severity of ulcerative colitis (52), and PAR-2 deficiency was protective in DSS-,2,4,6-trinitrobenzenesulfonic acid (TNBS)-and oxazolone-induced colitis (53). Most importantly, endogenous PAR-2 seemed to aggravate experimental colitis by inducing leukocyte recruitment toward the colon. In DSS-induced colitis, the lack of PAR-2 in hematopoietic cells did not protect the animals, suggesting an important role for the epithelial cells (54).

In conclusion, our data show that TF plays a detrimental role in experimental colitis. We suggest that TF-dependent PAR-2 activation in colon epithelial cells leads to local KC production, thereby provoking granulocyte influx with subsequent inflammation and organ damage.


The authors declare that they have no competing interests as defined by Molecular Medicine, or other interests that might be perceived to influence the results and discussion reported in this paper.


  1. Baumgart DC, Carding SR. (2007) Inflammatory bowel disease: cause and immunobiology. Lancet. 369:1627–40.

    Article  CAS  PubMed  Google Scholar 

  2. Borensztajn K, Peppelenbosch MP, Spek CA. (2009) Coagulation factor Xa signaling: the link between coagulation and inflammatory bowel disease? Trends Pharmacol. Sci. 30:8–16.

    Article  CAS  PubMed  Google Scholar 

  3. Strober W, Fuss I, Mannon P. (2007) The fundamental basis of inflammatory bowel disease. J. Clin. Invest. 117:514–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Cho JY, et al. (2007) Amelioration of dextran sulfate sodium-induced colitis in mice by oral administration of beta-caryophyllene, a sesquiterpene. Life Sci. 80:932–9.

    Article  CAS  PubMed  Google Scholar 

  5. Bernstein C, et al. (2001) The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population-based cohort study. Thromb. Haemost. 85:430–4.

    Article  CAS  PubMed  Google Scholar 

  6. Talbot RW, et al. (1986) Vascular complications of inflammatory bowel disease. Mayo Clin. Proc. 61:140–5.

    Article  CAS  PubMed  Google Scholar 

  7. Yoshida H, Granger DN. (2009) Inflammatory bowel disease: a paradigm for the link between coagulation and inflammation. Inflamm. Bowel Dis. 15:1245–55.

    Article  PubMed  Google Scholar 

  8. Graef V, Baggenstoss AH, Seaur WG. (1996) Venous thrombosis occurring in non-specific ulcerative colitis. Arch. Intern. Med. 17:377–82.

    Google Scholar 

  9. Danese S, et al. (2007) Inflammation and coagulation in inflammatory bowel disease: the clot thickens. Am. J. Gastroenterol. 102:174–86.

    Article  CAS  PubMed  Google Scholar 

  10. Thompson NP, Wakefield AJ, Pounder RE. (1995) Inherited disorders of coagulation appear to protect against inflammatory bowel disease. Gastroenterology. 108:1011–5.

    Article  CAS  PubMed  Google Scholar 

  11. Vrij AA, et al. (2001) Low molecular weight heparin treatment in steroid refractory ulcerative colitis: clinical outcome and influence on mucosal capillary thrombi. (2001) Scand. J. Gastroenterol. Suppl. 234:41–7.

    Article  Google Scholar 

  12. Gaffney PR, et al. (1995) Paradoxical response to heparin in 10 patients with ulcerative colitis. Am. J. Gastroenterol. 90:220–3.

    CAS  PubMed  Google Scholar 

  13. Torkvist L, et al. (1999) Low molecular weight heparin as adjuvant therapy in active ulcerative colitis. Aliment Pharmacol. Ther. 13:1323–8.

    Article  CAS  PubMed  Google Scholar 

  14. Folwaczny C, Wiebecke B, Loeschke K. (1999) Unfractioned heparin in the therapy of patients with highly active inflammatory bowel disease. Am. J. Gastroenterol. 94:1551–5.

    Article  CAS  PubMed  Google Scholar 

  15. Bloom S, et al. (2004) Low molecular weight heparin (tinzaparin) vs. placebo in the treatment of mild to moderately active ulcerative colitis. Aliment Pharmacol. Ther. 19:871–8.

    Article  CAS  PubMed  Google Scholar 

  16. Spek CA, ten Kate FJ, te Velde AA. (2007) Factor V Leiden and the etiology of inflammatory bowel disease. Thromb. Haemost. 98:670–3.

    Article  CAS  PubMed  Google Scholar 

  17. Osterud B, Rapaport SI. (1977) Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation. Proc. Natl. Acad. Sci. U. S. A. 74:5260–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Nemerson Y. (1988) Tissue factor and hemostasis. Blood. 71:1–8.

    CAS  PubMed  Google Scholar 

  19. Ruf W, Dorfleutner A, Riewald M. (2003) Specificity of coagulation factor signaling. J. Thromb. Haemost. 1:1495–503.

    Article  CAS  PubMed  Google Scholar 

  20. Camerer E, et al. (2000) Binding of factor VIIa to tissue factor on keratinocytes induces gene expression. J. Biol. Chem. 275:6580–5.

    Article  CAS  PubMed  Google Scholar 

  21. Johnson K, et al. (1998) Potential mechanisms for a proinflammatory vascular cytokine response to coagulation activation. J. Immunol. 160:5130–5.

    CAS  PubMed  Google Scholar 

  22. Schoenmakers SH, et al. (2004) Tissue factor haploinsufficiency during endotoxin induced coagulation and inflammation in mice. J. Thromb.Haemost. 2:2185–93.

    Article  CAS  PubMed  Google Scholar 

  23. Taylor FB Jr, et al. (1991) Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody. Circ. Shock. 33:127–34.

    PubMed  Google Scholar 

  24. Dackiw AP, et al. (1996) Prevention of endotoxin-induced mortality by antitissue factor immunization. Arch. Surg. 131:1273–8.

    Article  CAS  PubMed  Google Scholar 

  25. Taylor FB, et al. (1998) Active site inhibited factor VIIa (DEGR VIIa) attenuates the coagulant and interleukin-6 and -8, but not tumor necrosis factor, responses of the baboon to LD100 Escherichia coli. Blood. 91:1609–15.

    CAS  PubMed  Google Scholar 

  26. Anthoni C, et al. (2007) Tissue factor: a mediator of inflammatory cell recruitment, tissue injury, and thrombus formation in experimental colitis. J. Exp. Med. 204:1595–601.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Parry GC, et al. (1998) Low levels of tissue factor are compatible with development and hemostasis in mice. J. Clin. Invest. 101:560–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Myint KM, et al. (2006) RAGE control of diabetic nephropathy in a mouse model: effects of RAGE gene disruption and administration of low-molecular weight heparin. Diabetes. 55:2510–22.

    Article  CAS  PubMed  Google Scholar 

  29. van Dop WA, et al. (2010) The absence of functional PI3Kgamma prevents leukocyte recruitment and ameliorates DSS-induced colitis in mice. Immunol. Lett. 131:33–9.

    Article  PubMed  Google Scholar 

  30. Snoek SA, et al. (2010) Selective alpha7 nicotinic acetylcholine receptor agonists worsen disease in experimental colitis. Br. J. Pharmacol. 160:322–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Slofstra SH, et al. (2007) Gene expression profiling identifies C/EBPδ as a candidate regulator of endotoxin-induced disseminated intravascular coagulation. Am. J. Resp. Crit. Care Med. 176:602–9.

    Article  CAS  PubMed  Google Scholar 

  32. Schoenmakers SH, et al. (2004) Tissue factor haploinsufficiency during endotoxin induced coagulation and inflammation in mice. J. Thromb. Haemost. 2:2185–93.

    Article  CAS  PubMed  Google Scholar 

  33. Borensztajn K, Peppelenbosch MP, Spek CA. (2010) Coagulation factor Xa inhibits cancer cell migration via LIMK1-mediated cofilin inactivation. Thromb. Res. 125:e323–8.

    Article  CAS  PubMed  Google Scholar 

  34. Bijlsma MF, et al. (2007) Sonic hedgehog induces transcription-independent cytoskeletal rearrangement and migration regulated by arachidonate metabolites. Cell Signal. 19:2596–604.

    Article  CAS  PubMed  Google Scholar 

  35. Schaffner F, Ruf W. (2009) Tissue factor and PAR2 signaling in the tumor microenvironment. Arterioscler. Thromb. Vasc. Biol. 29:1999–2004.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Jiang X, et al. (2008) Formation of tissue factor-factor VIIa-factor Xa complex induces activation of the mTOR pathway which regulates migration of human breast cancer cells. Thromb. Haemost. 100:127–33.

    Article  CAS  PubMed  Google Scholar 

  37. Brown PW, Bargen J, Weber HA. (1934) Chronic inflammatory lesions of the small intestine (regional enteritis). Am. J. Dig. Dis. 1:426–31.

    Article  Google Scholar 

  38. Feagan BG, et al. (2005) Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N. Engl. J. Med. 352:2499–507.

    Article  CAS  PubMed  Google Scholar 

  39. Targan SR, et al. (2007) Natalizumab for the treatment of active Crohncs disease: results of the ENCORE Trial. Gastroenterology. 132:1672–83.

    Article  CAS  PubMed  Google Scholar 

  40. Osterud B. (2010) Tissue factor expression in blood cells. Thromb. Res. 125 Suppl 1:S31–4.

    Article  PubMed  Google Scholar 

  41. Shea-Donohue T, et al. (2008) Mice deficient in the CXCR2 ligand, CXCL1 (KC/GRO-alpha), exhibit increased susceptibility to dextran sodium sulfate (DSS)-induced colitis. Innate Immun. 14:117–24.

    Article  CAS  PubMed  Google Scholar 

  42. Chien-Huang Lin, et al. (2006) c-Src mediates thrombin-induced NF-κB activation and IL-8/CXCL8 expression in lung epithelial cells. J. Immunol. 177:3427–38.

    Article  Google Scholar 

  43. Lin CH, et al. (2011) Thrombin induces NF-kappaB activation and IL-8/CXCL8 expression in lung epithelial cells by a Rac1-dependent PI3K/Akt pathway. J. Biol. Chem. 286:10483–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Izzo RS, et al. (1992) Interleukin-8 and neutrophil markers in colonic mucosa from patients with ulcerative colitis. Am. J. Gastroenterol. 87:1447–52.

    CAS  PubMed  Google Scholar 

  45. Mazzucchelli L, et al. (1994) Expression of interleukin-8 gene in inflammatory bowel disease is related to the histological grade of active inflammation. Am. J. Pathol. 144:997–1007.

    CAS  PubMed  PubMed Central  Google Scholar 

  46. Schuerer-Maly CC, et al. (1993) Interleukin-1 and experimental gastric ulcer healing in the rat. J. Physiol. Pharmacol. 44:23–9.

    CAS  PubMed  Google Scholar 

  47. Demetz G, et al. (2010) Tissue factor-factor VIIa complex induces cytokine expression in coronary artery smooth muscle cells. Atherosclerosis. 212:466–71.

    Article  CAS  PubMed  Google Scholar 

  48. Wang X, Gjernes E, Prydz H. (2002) Factor VIIa induces tissue factor-dependent up-regulation of interleukin-8 in a human keratinocyte line. J. Biol.Chem. 277:23620–6.

    Article  CAS  PubMed  Google Scholar 

  49. Hjortoe GM, et al. (2004) Tissue factor-factor VIIa-specific up-regulation of IL-8 expression in MDA-MB-231 cells is mediated by PAR-2 and results in increased cell migratiom. Blood. 103:3029–37.

    Article  CAS  PubMed  Google Scholar 

  50. Wang H, et al. (2010) Proteinase-activated receptors induce interleukin-8 expression by intestinal epithelial cells through ERK/RSK90 activation and histone acetylation. FASEB J. 24:1971–80.

    Article  CAS  PubMed  Google Scholar 

  51. Tanaka Y, et al. (2008) PAR2 triggers IL-8 release via MEK/ERK and PI3-kinase/Akt pathways in GI epithelial cells. Biochem. Biophys. Res. Commun. 377:622–6.

    Article  CAS  PubMed  Google Scholar 

  52. Tahara T, et al. (2009) Promoter methylation of protease-activated receptor (PAR2) is associated with severe clinical phenotypes of ulcerative colitis (UC). Clin. Exp. Med. 9:125–30.

    Article  CAS  PubMed  Google Scholar 

  53. Hyun E, et al. (2008) Protease-activated receptor-2 activation: a major actor in intestinal inflammation. Gut. 57:1222–9.

    Article  CAS  PubMed  Google Scholar 

  54. Hyun E, et al. (2010) Contribution of bone marrow-derived cells to the pro-inflammatory effects of protease-activated receptor-2 in colitis. Inflamm. Res. 59:699–709.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references


We would like to thank Joost Daalhuisen, Marieke ten Brink and Danielle Kruijswijk for expert technical assistance. This work is supported by grant WO 06-02 of the Dutch Digestive Diseases Foundation (Maag Lever Darm Stichting [MLDS]).

Author information

Authors and Affiliations


Corresponding author

Correspondence to C. Arnold Spek.

Rights and permissions

Open Access This article is published under license to BioMed Central Ltd. This is an Open Access article is distributed under the terms of the Creative Commons Attribution License ( ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and Permissions

About this article

Cite this article

Queiroz, K.C.S., van’t Veer, C., van den Berg, Y. et al. Tissue Factor-Dependent Chemokine Production Aggravates Experimental Colitis. Mol Med 17, 1119–1126 (2011).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:


  • Experimental Colitis
  • Dextran Sulfate Sodium (DSS)
  • Granulocyte Influx
  • Tissue Factor
  • Keratinocyte-derived Chemokine (KC)